People with diabetes have new, low-cost option for insulin (31 Aug 2000)
Wal-Mart, Novo Nordisk introduce co-branded insulin
Princeton, NJ - As health care costs continue to rise, people with diabetes have a new, low-cost option for one of their primary medical needs. Wal-Mart and Novo Nordisk Pharmaceuticals, Inc today introduced Novolin® human insulins (rDNA) to Wal-Mart's ReliOn® brand of diabetes health care products. Now available in all Wal-Mart and SAM'S Club pharmacies nationwide, the products will deliver an exceptional value for people who depend on human insulin for the day-to-day management of diabetes.
"Wal-Mart recognises the financial burden that can sometimes impact patient compliance to a prescribed therapy," said Frank Segrave, vice president divisional merchandise manager for Wal-Mart Pharmacy. "By expanding the ReliOn® portfolio to include Novolin® human insulin we have combined the strength of two powerful health care brands to provide the highest quality product at an affordable price."
Novolin® human insulin will be available under the ReliOn® brand for USD 16.94 for a 10 ml vial. It is the latest addition to Wal-Mart's growing ReliOn® brand of health care products which include ReliOn® Insulin Syringes, ReliOn® Glucose Tablets, ReliOn® Blood Pressure Monitors and ReliOn® Lancets.
"We believe that this alliance will help the millions of Americans who are managing their diabetes to have easier, affordable access to this life-saving drug," said Martin Soeters, president of Novo Nordisk Pharmaceuticals, Inc.
Diabetes is the seventh leading cause of death in the United States. Approximately 16 million Americans have the disease, and approximately 798,000 new cases are diagnosed per year. In terms of health care, diabetes costs the nation more than USD 90 billion per year.
In addition to its ReliOn® brand of diabetes health care products, Wal-Mart will launch an in-store initiative in September to reach out to the one-third of Americans with diabetes who are unaware they have the disease. Wal-Mart's Healthy Living: Diabetes Living campaign will include diabetes risk tests for customers, information for people who may be at risk, and health tips and resources to people with diabetes.
According to the Diabetes Control and Complications Trial study (DCCT), tighter blood glucose control plays a critical role in helping people with diabetes delay or avoid the many complications of the disease, including blindness, kidney failure, strokes and neurological disorders.
Under the ReliOn® brand, Novolin® human insulin will be offered in three human insulin formulations: Novolin® R (Regular), Novolin® N (NPH) and Novolin® 70/30 (70% NPH, 30 % Regular).
Consumers are reminded to consult with their physician before making any changes in insulin therapy.